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Background: Pancreatic cancer is a highly lethal disease and has the worst prognosis of any major malignancy.
G protein-coupled receptor GPR87 is reported to be overexpressed in multiple cancers. The clinical significance
and biological role of GPR87 in pancreatic cancer, however, remain to be established.
Methods: GPR87 expression in pancreatic cancer cell lines, paired patient tissues were determined using western
blotting and Real-time PCR. Ninety-six human pancreatic cancer tissue samples were analyzed by immunochemistry
(IHC) to investigate the association between GPR87 expression and the clinicopathological characteristics of pancreatic
cancer. Functional assays, such as anchorage-independent growth, chicken chorioallantoic membrane (CAM) assay,
transwell matrix penetration assay, and Annexin V-FITC and PI staining and a xenograft tumor model were used
to determine the oncogenic role of GPR87 in human pancreatic cancer progression. The effect of GPR87 on NF-κB
signaling pathway was further investigated using the luciferase reporter assays, and by detection of the NF-κB
signaling downstream genes.
Results: Herein, we reported that GPR87 was markedly overexpressed in pancreatic cancer cells and clinical
tissues. Immunohistochemical analysis showed that the expression of GPR87 significantly correlated with patients’
clinicopathologic features, including clinical stage and tumor-nodule-metastasis (TNM) classification. Pancreatic
cancer patients with higher levels of GPR87 expression had shorter overall survival compared to patients with
lower GPR87 levels. We gained valuable insights into the mechanism of GPR87 expression in pancreatic cancer
cells by demonstrating that overexpressing GPR87 significantly enhanced, whereas silencing endogenous GPR87
inhibited, the proliferation, angiogenesis and increased resistance to gemcitabine-induced apoptosis of pancreatic
cancer in vitro and tumorigenicity of pancreatic cancer cells in vivo. Finally, we demonstrated that GPR87 enhanced
pancreatic cancer aggressiveness by activating NF-κB signaling pathway. Conclusions: Taken together, these findings
suggest that GPR87 plays a critical oncogenic role in pancreatic cancer progression and highlight its potential as a
target for pancreatic cancer therapy.
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Conclusions: Our findings suggest that GPR87 plays a critical oncogenic role in pancreatic cancer progression and
highlight its potential as a target for pancreatic cancer therapy.
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Pancreatic cancer is one of the most aggressive and lethal
malignancies and ranks as the eighth most common cause
of death from cancer worldwide [1, 2]. Despite the wide
application of surgical resection, chemotherapy and/or
chemoradiotherapy, pancreatic cancer still has the worst
prognosis of any major malignancy with a 5-year survival
rate of <5% and a median survival of <6 months [3, 4].
Therefore, it will be of great clinical value to identify
effective treatment strategies and explore the molecular
mechanisms responsible for the pathogenesis of pan-
creatic cancer to improve the prognosis of pancreatic
cancer patients.
Increasing evidence suggests that unsatisfactory thera-
peutic outcomes and the poor prognosis associated with
pancreatic cancer are related to aberrantly activated sig-
naling pathways, including NF-κB signaling [5, 6]. Con-
stitutive activation of NF-κB signaling pathway plays an
important role in the development and progression of
pancreatic cancer and contributes to a malignant pheno-
type. Arlt et al. reported that constitutive NF-κB activity
confers resistance to gemcitabine-induced cell death in
pancreatic cancer, while inhibition of NF-κB strongly
diminishes gemcitabine resistance [5]. Maier and col-
leagues showed that NF-κB activation contributes to
epithelial-mesenchymal transition, migration and inva-
sion of pancreatic carcinoma cells, while these malignant
phenotypes are suppressed upon NF-κB inhibition [7]. It
has been reported that activation of NF-κB signaling
pathway also promotes pancreatic tumor angiogenesis
[8] and metastasis [8, 9]. Conversely, inhibition of NF-κB
signaling pathway increases the number of apoptotic
pancreatic cells [10] and inhibiting constitutive NF-κB
activity by expressing phosphorylation defective IκBα
significantly suppresses pancreatic cancer cell tumori-
genesis [11]. Therefore, identifying novel molecules that
modulate the NF-κB signaling pathway could be important
for pancreatic cancer therapy.
G protein-coupled receptor (GPCR) 87, a newly identi-
fied gene located on chromosome 3q24, encodes a pro-
tein that contains an extracellular N terminus, seven
helices, three intracellular loops, three extracellular
loops and an intracellular C terminus [12]. It is a cell
surface GPCR that is overexpressed in various cancers
and plays vital role in tumor cell survival [13, 14]. A pre-
vious study using GPCR-focused Affymetrix microarrays
to examine the expression of 929 GPCR transcripts intissue samples from 10 patients with lung squamous cell
carcinoma identified GPR87 as one of five GPCRs sig-
nificantly overexpressed in this disease [15]. NII and
colleagues reported that overexpression of GPR87 in
non-small cell lung carcinoma (NSCLC) is significantly
correlated with poorer differentiation and that higher
expression of GPR87 is significantly associated with
poorer survival for patients with NSCLC [16]. More-
over, GPR87 is essential for p53-dependent cell survival
of RKO and MCF7 cell lines in response to DNA dam-
age induced by doxorubicin or camptothecin and may
serve as a novel therapeutic target for cancer treatment
and prevention [17]. Zhang et al. reported that GPR87
is overexpressed in bladder cancer and promotes cell
proliferation in bladder cancer cells [18]. Importantly,
overexpression of GPR87 upregulates expression of
cancer stem cell marker CD133 and promotes the
growth and metastasis of CD133+ cancer stem-like cells
in hepatocellular carcinoma [19].
Herein, we reported that GPR87 expression was sig-
nificantly upregulated in pancreatic cancer and clinical
tissues, and was correlated with the clinical features of
pancreatic cancer. Overexpression of GPR87 promotes
proliferation, metastasis, angiogenesis and resistance to
apoptosis induced by a chemotherapeutic agent in pan-
creatic cancer. Our findings suggest that GPR87 plays a
critical oncogenic role in pancreatic cancer progression
and highlight its potential as a target for pancreatic
cancer therapy.
Results
GPR87 overexpression is correlated with pancreatic
cancer progression and poor prognosis
By analyzing datasets from The Cancer Genome Atlas
(TCGA) and GSE16515 (http://www.ebi.ac.uk/arrayex-
press/experiments/E-GEOD-16515/?query=gse16515.),
we found that GPR87 expression was significantly upreg-
ulated in primary pancreatic cancer tissues compared
with normal pancreatic tissue (Fig. 1a). Kaplan-Meier
survival analysis of data from TCGA revealed that pan-
creatic cancer patients with higher expression of GPR87
had shorter overall survival (Fig. 1b). Western Blot and
real-time PCR was performed and showed that GPR87
expression was upregulated in the six pancreatic cancer
cell lines compared with normal human pancreatic
ductal epithelial cells (HPDECs; Fig. 1c and Additional
file 1: Figure S1A). Consistent with these findings,
Fig. 1 Overexpression of GPR87 correlates with pancreatic carcinoma progression and poor prognosis. a. Expression profile of GPR87 mRNA in
primary pancreatic cancer tissues (n = 178) and normal pancreatic tissues (n = 4; p < 0.01; TCGA) (left panel); expression profile of GPR87 mRNA in
primary pancreatic cancer tissues (n = 36) and normal pancreatic tissues (n = 16; p < 0.01; GSE16515) (right panel). b. Kaplan-Meier survival curves
comparing pancreatic cancer patients with low and high GPR87 expression levels (n = 115; p < 0.027; TCGA). Higher and lower expression was
based on median value of GPR87 mRNA. c. Western blot analysis of GPR87 expression in human pancreatic ductal epithelial cells (HPDECs) and
six pancreatic cancer cell lines. d. Expression of GPR87, as determined by Western blot, in eight paired primary pancreatic cancer tissues (T) and
the matched adjacent non-tumor tissues (ANT) from the same patient. α-tubulin served as a loading control. e. IHC staining indicating GPR87
protein expression in human primary pancreatic cancer compared with adjacent pancreatic tissues. f. Kaplan–Meier analysis of overall survival
stratified by low GPR87 expression (n = 47) and high GPR87 expression (n = 49). GPR87 upregulation was significantly correlated with shorter
overall survival (p = 0.040)
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overexpressed in eight primary pancreatic cancer sam-
ples with matched adjacent normal pancreatic tissues
(Fig. 1d and Additional file 1: Figure S1B). These findings
confirmed the data obtained from TCGA and the results
from cell lines, suggesting that GPR87 is overexpressed in
human pancreatic cancer.
To determine the clinical relevance of GPR87 in
pancreatic cancer, GPR87 was examined in 96 paraffin-
embedded, archived pancreatic cancer tissues by immu-
nohistochemistry (IHC; (Additional file 2: Table S1). As
shown in Fig. 1e, GPR87 was significantly upregulated
in pancreatic tumors compared with matched adjacent
normal pancreatic tissues. Furthermore, GPR87 levelswere correlated with clinical stage (p = 0.022), and
TNM classification (T: p = 0.003, N: p = 0.001, M: p <
0.001) in patients with pancreatic cancer (Additional
file 3: Table S2). Kaplan-Meier survival analysis revealed
that higher expression of GPR87 correlated with shorter
overall survival (Fig. 1f). Collectively, these findings sug-
gest a potential association between GPR87 upregulation
and progression of pancreatic cancer.
Upregulation of GPR87 promotes the aggressiveness of
pancreatic cancer in vitro
To explore the biological role of GPR87 overexpression in
pancreatic cancer progression, PANC-1 and AsPC-1 cell
lines stably overexpressing GPR87 were established (Fig. 2a).
Fig. 2 Upregulation of GPR87 expression promotes pancreatic cancer cell aggressiveness in vitro. a. Western blot of GPR87 expression in PANC-1
and AsPC-1 cells stably overexpressing GPR87. α-tubulin was used as a loading control. b. Representative images (left panel) and quantification
(right panel) of colonies in an anchorage-independent growth assay. Colonies larger than 0.1 mm in diameter were scored. c. Representative
micrographs (left panel) and quantification (right panel) of BrdU labeling in cells transfected with GPR87 or a vector control. d. Representative
images (left panel) and quantification (right panel) of HUVECs cultured on matrigel-coated plates with conditioned medium from vector control
or GPR87-transduced pancreatic cancer cells. e. Representative images of CAM blood vessels stimulated with conditioned medium from the indicated
cells. f. Representative images (upper panel) and quantification (lower panel) of invading cells based on a transwell matrix penetration assay. g.
Representative images (left panel) and quantification (right panel) of Annexin V-FITC and PI staining of PANC-1 and AsPC-1 cells overexpressing
GPR87 treated with gemcitabine (1 μM) for 24 h. Each bar represents the mean ± SD of three independent experiments. * p < 0.05
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of GPR87-overexpressing pancreatic cancer cells dra-
matically augmented up to 2 folds compared to control
cells (Fig. 2b). Furthermore, BrdU incorporation assay
was performed and showed that only approximately 25
~ 28% of control cells incorporated BrdU as compared
with about 45 ~ 50% of GPR87-transduced cells, indi-
cating that overexpressing GPR87 significantly increased
the growth rate of pancreatic cells (Fig. 2b). In addition,
the ability of pancreatic cancer cells to induce humanumbilical vein endothelial cell (HUVEC) tube formation,
as indicated by the drastic increased length of the com-
pleted tubes, and chicken chorioallantoic membrane
(CAM) neovascularization, and invasive capability was
markedly increased in the GPR87-overexpressing pan-
creatic cells (Fig. 2d-f ). Moreover, overexpression of
GPR87 also increased the resistance of pancreatic cancer
cells to apoptosis induced by chemotherapeutic agents
gemcitabine (Fig. 2g). Furthermore, we also found that
overexpressing GPR87 or silencing GPR87 only resulted
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cells without any treatment (Additional file 4: Figure S2A).
Taken together, these results suggest that GPR87 overex-
pression promotes the aggressiveness of pancreatic cancer
cells in vitro.
Silencing GPR87 suppresses the aggressiveness of
pancreatic cancer cells in vitro
Downregulation of GPR87 significantly inhibited prolifera-
tion of pancreatic cells (Fig. 3a-c), as shown nearly 2- to
2.5-fold decreased colonies and up to 2.5- to 5-fold
reduced BrdU-positive cells in GPR87-silenced pancreatic
cancer cells compared to control cells. In addition, silen-
cing GPR87 decreased the invasive capacity of pancreatic
cells as evaluated by the Transwell Cell invasion Matrigel
Assay (Fig. 3d). Furthermore, HUVEC tube formation and
CAM assays showed the abilities of pancreatic cancer
cells to induce HUVEC tube formation and CAM neo-
vascularization were inhibited in response to GPR87
knockdown (Fig. 3e-f ). While Annexin V assay showed
that the sensitivity of GPR87-silenced pancreatic cells
to gemcitabine or Fluorouracil was drastically increased
compared with control cells (Fig. 3g and Additional file 4:
Figure S2B). Together, these data indicate that downregu-
lation of GPR87 expression inhibits pancreatic cancer
aggressiveness in vitro.
Overexpression of GPR87 contributes to pancreatic
cancer progression in vivo
To examine the biological effects of GPR87 on pancreatic
cancer progression, a xenograft tumor model was used.
As shown in Fig. 4a-c and Additional file 5: Figure S3,
tumors formed by GPR87-overexpressing PANC-1 cells
were larger and heavier than the tumors formed by con-
trol cells. Conversely, tumors formed by GPR87-silenced
PANC-1 cells were smaller and had lower tumor weights
than the control tumors. Furthermore, IHC analysis
revealed that GPR87-overexpressing tumors showed
higher percentages of Ki-67-positive cells, greater micro-
vascular density (MVD) and fewer TUNEL-positive cells,
whereas GPR87-silenced tumors displayed lower Ki-67
proliferation index and MVD and an increased percentage
of TUNEL-positive apoptotic cells compared with control
cells (Fig. 4d). Collectively, our findings emphasize the
role of oncogenic GPR87 in pancreatic cancer progres-
sion in vivo.
GPR87 overexpression activates the NF-κB signaling
pathway in pancreatic cancer
By analyzing GPR87 mRNA expression and NF-κB-
regulated gene signatures from published pancreatic can-
cer patient profiles (TCGA datasets), we found that GPR87
expression was positively correlated with NF-κB signaling
gene signatures (Fig. 5a and Additional file 6: Figure S4),raising the possibility that GPR87 upregulation may acti-
vate NF-κB signaling pathway in pancreatic cancer. In
agreement with this supposition, NF-κB luciferase reporter
activity was significantly increased in the GPR87-
overexpressing cells but decreased in the GPR87-silenced
cells (Fig. 5b). Moreover, the expressions of numerous
well-known NF-κB downstream genes were shown to be
elevated in GPR87-overexpressing cells but reduced in
GPR87-silenced cells (Fig. 5c). Furthermore, western
blotting revealed that the expression of nuclear p65
and phosphorylated-IKKβ and p-IκBα were signifi-
cantly increased in GPR87-overexpressing cells but
decreased in GPR87-silenced cells (Fig. 5d), suggesting
that GPR87 promotes the activation of NF-κB signaling
pathway.
To explore whether GPR87 mediates pancreatic can-
cer progression through NF-κB activation, luciferase
reporter analysis was performed. Our results showed
that the stimulatory effect of GPR87 on NF-κB activa-
tion was significantly inhibited by transfection of an
IκBα dominant-negative mutant (IκBα-mut) or treat-
ment with an NF-κB inhibitor. In addition, blockage of
NF-κB signaling by either ectopically expressing IκBα-
mu or treatment with NF-κB inhibitor drastically de-
creased colony numbers formed by GPR87-transduced
cells in soft agar and reduced the capability of GPR87
overexpression induced invasiveness and angiogenesis
(Fig. 5e-g). Furthermore, we found that the effects of
NF-κB inhibitor in GPR87-overexpressing cells were
much higher than that in naïve cells, and GPR87-RNAi
treated cells only showed minimal response to NF-κB
inhibitor (Fig. 5e-g and Additional file 7: Figure S5A-C).
These results suggest that functional NF-κB activation
is critical for GPR87-mediated aggressiveness of pan-
creatic cancer cells.Clinical relevance of GPR87-induced NF-κB activation in
human pancreatic cancer
To further determine the clinical correlation between
GPR87 and NF-κB signaling pathway, we examined
whether GPR87 induced p65 nuclear accumulation in
pancreatic cancer and elevated expression of NF-κB
downstream genes in clinical samples. As shown in
Fig. 6, GPR87 levels were positively correlated with
nuclear p65 expression (r = 0.709, p = 0.022) and the
mRNA expression levels of NF-κB downstream genes,
Bcl-xL (r = 0.660, p = 0.038), CCND1 (r = 0.763, p = 0.010)
and VEGF-C (r = 0.687, p = 0.028) in ten freshly collected
clinical pancreatic cancer samples. Therefore, these results
further support that GPR87 upregulation promotes the
aggressiveness of pancreatic cancer and activates the
NF-κB signaling pathway, which potentially leads to
poor outcomes for patients with pancreatic cancer.
Fig. 3 (See legend on next page.)
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Fig. 3 Downregulation of GPR87 decreases the aggressiveness of pancreatic cancer cells. a. Western blot analysis of GPR87 expression in PANC-1
and AsPC-1 cells following GPR87 silencing by RNAi. α-tubulin was used as a loading control. b. Representative images (left panel) and quantification
(right panel) of colonies in an anchorage-independent growth assay. Colonies larger than 0.1 mm in diameter were scored. c. Representative
micrographs (left panel) and quantification (right panel) of BrdU labeling in cells transfected with GPR87-RNAi or an RNAi-vector. d. Representative
images (left panel) and quantification (right panel) of HUVECs cultured on matrigel-coated plates with conditioned medium from control and
GPR87-RNAi pancreatic cancer cells. e. Representative images of CAM blood vessels stimulated with conditioned medium from the indicated
cells. f. Representative images (upper panel) and quantification (lower panel) of invaded cells analyzed using a transwell matrix penetration assay.
g. Representative images (left panel) and quantification (right panel) of Annexin V-FITC and PI staining of indicated cells treated with gemcitabine
(1 μM) for 24 h. Each bar represents the mean ± SD of three independent experiments. * p < 0.05
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In the present study, we provided evidence for a novel
link between GPR87 and the oncogenic NF-κB signaling
pathway in pancreatic cancer. IHC analysis revealed that
GPR87 was significantly upregulated in pancreatic
cancer and correlated with clinical features and a poor
prognosis of pancreatic cancer patients. OverexpressionFig. 4 Overexpression of GPR87 contributes to pancreatic cancer progressi
tumors from mice in each group (right). b. Tumor volumes were measured on
that overexpression of GPR87 induces while suppression of GPR87 inhibits the
the expression of Ki67 and CD31 as well as TUNEL-positive cells. * p < 0.0of GPR87 dramatically increased the anchorage-
independent growth ability and the invasive capacity of
pancreatic cells, promoted their ability to induce
HUVEC tube formation and CAM neovascularization,
and enhanced their resistance to apoptosis, while down-
regulation of GPR87 expression produced the opposite
effects. These findings emphasize the prominent roles ofon in vivo. a. Representative images of tumor-bearing mice (left) and
the indicated days. c. Mean tumor weights. d. IHC staining demonstrating
aggressive phenotype of pancreatic cancer cells in vivo, as indicated by
5
Fig. 5 (See legend on next page.)
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Fig. 5 GPR87 up-regulation activates the NF-κB signaling pathway in pancreatic cancer. a. GSEA plots, demonstrating a significant correlation
between the GPR87 mRNA expression levels in pancreatic cancer and the NF-κB-activated gene signatures from published datasets. b. Analysis of
luciferase reporter activity in the indicated cells following transfection with 100 ng pNF-κB-luc plasmids or control-luciferase plasmid. c. Real-time
PCR analysis demonstrating an apparent overlap between NF-κB-dependent gene expression and GPR87-regulated gene expression. The pseudo
color represents an intensity scale for GPR87 versus vector or GPR87 siRNA versus control siRNA, calculated by log2 transformation. d. Western
blotting analysis of the expression levels of the indicated proteins in the indicated cells. α-tubulin was used as a loading control. e. Quantification
of colony numbers as determined by anchorage-independent growth assay. Colonies larger than 0.1 mm in diameter were scored. f. Quantification of
tubule formation by HUVECs cultured in matrigel-coated plates with conditioned media from pancreatic cancer cells transfected with the vector,
IκBα-mut or treated with the NF-κB inhibitor (JSH-23). g. Quantification of gemcitabine-induced (1 μM) TUNEL-positive cells in pancreatic cells
transfected with vector, IκBα-mut or treated with the NF-κB inhibitor. Each bar represents the mean ± SD of three independent experiments. *p < 0.05
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gression of pancreatic cancer via NF-κB signaling
pathway.
It is well established that the NF-κB signaling pathway
not only regulates immune and inflammatory responses,
but also plays an important role in oncogenesis [20, 21].
Therapeutic targeting of NF-κB signaling has been ag-
gressively pursued for the treatment of a wide range of
malignant pathologies in pancreatic cancer [5, 22–24].
Inhibition of NF-κB pathway by MG132, or sulfasalazine
dramatically diminishes resistance to apoptosis induced
by gemcitabine in multiple pancreatic cancer cell lines
[5]. Additionally, NF-κB pathway inhibitor sodium sali-
cylate inhibits phosphorylation and degradation of NF-
κB negative regulator IκBα and subsequently enhances
TNF-α induced apoptosis in BxPC-3 human pancreatic
cancer cells [22]. Treatment with nafamostat mesilate,
an NF-κB inhibitor, significantly decreases the volume
and weight of nude mice xenografts derived from pan-
creatic cancer cells compared with the control group
[23]. Furthermore, a nude mouse model was established
and revealed that the number of liver metastases derived
from pancreatic cancer cells was significantly decreasedFig. 6 Clinical relevance of GPR87-induced NF-κB activation in human pan
expression and BCL-xL, CCND1, VEGF-C and nuclear p65 expression in 10 fr
nuclear protein p84 were used as loading controls. Each bar represents the min the treatment group with the NF-κB inhibitor
DHMEQ, compared with the control group [24]. Col-
lectively, these findings provide a strong rationale for
therapeutic targeting NF-κB signaling pathway in
pancreatic cancer. Nevertheless, it is still a formidable
challenge to archive improved treatment outcomes up to
now. Although potential therapeutic approaches, such as
the use of NF-κB or IKKβ inhibitors, could potentially
exert anti-tumor effects on the cancer-promoting activities
of NF-κB, they interfere with its various physiological
functions in normal cells, such as functions in immunity
and inflammation [21, 25]. Therefore, more effective
therapeutic targets that regulate NF-κB signaling in an
appropriate manner is warranted as an alternative to glo-
bal NF-κB blockade. Herein, our study showed that
GPR87 was overexpressed in pancreatic cancer and asso-
ciated with poor survival of pancreatic cancer patients.
Overexpressing GPR87 significantly promoted malignant
phenotype including increased proliferation, angiogenesis,
invasion and resistance to chemotherapeutic agent via
impairing NF-κB signaling, while silencing GPR87 sup-
pressed these effects. Meanwhile, we found that overex-
pressing GPR87 in HPDEC-1 dramatically increased thecreatic cancer. Expression analysis (left) and correlation (right) of GPR87
eshly collected human pancreatic tumor samples (T); α-Tubulin and the
ean ± SD of three independent experiments
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(Additional file 8: Figure S6A-C). Furthermore, overex-
pression of GPR87 could also increase the proliferating
rate of the esophageal squamous cell carcinoma (ESCC)
cells (Additional file 8: Figure S6D-F), while silencing
GPR87 produced the opposite effects, providing further
evidence that GPR87 function as an onco-protein.
GPCRs represent the largest family of cell-surface
molecules involved in signal transmission by far with
more than 800 members, accounting for >2% of the total
genes encoded by the human genome. These receptors
regulate many cell functions, including cell proliferation,
survival and motility, and have recently emerged as key
players in processes contributing to tumor progression
such as tumor growth, angiogenesis and metastasis [26].
GPR55, for example, has been reported to be upregu-
lated in human squamous cell carcinomas and to
enhance skin cancer cell anchorage-independent growth,
invasiveness and tumorigenicity in vivo [27]. Overex-
pression of PAR1, a GPCR, promotes invasion and
metastasis in breast cancer cells and inhibition of PAR1
signaling suppresses HMGA2-driven invasion in breast
cancer cells [28]. P2Y2, a GPCR, is significantly overex-
pressed in prostate cancer and promotes cell invasion
and metastasis both in vitro and in vivo [29]. Stevenson
et al. reported that silencing the GPCR G-protein–
coupled receptor galanin receptor 1 (GalR1) enhanced
the effects of chemotherapy in drug-sensitive and resistant
colorectal cancer cell lines [30]. Herein, we found that
GPR87 was upregulated in pancreatic cancer and GPR87
overexpression promoted pancreatic tumor progression
both in vivo and in vivo, which is in agreement with the
oncogenic effects of GPR87 family members.
Accumulating evidence suggests that NF-κB signaling
pathway can be activated by members of the GPCR family.
Liu et al. reported that somatostatin type 2 receptor
(SSTR2), a member of the GPCRs, activates NF-κB sig-
naling pathway by leading to phosphorylation of IKKα/β
and degradation of IκBα in pancreatic tumor cell line
AR42J [31]. A previous study revealed that CXCL12
specifically signals through CXCR4, a member of the
GPCRs to activate Akt and ERK and subsequently
phosphorylate IκBα, causing activation of NF-κB signal-
ing in pancreatic cancer cells [32]. Additionally, Lee
and colleagues reported that activation of the BLT2 (a
GPCR)-linked pathway leads to NOX-derived ROS
generation and subsequent activation of NF-κB in pros-
tate cancer cells [33]. Concordant with previous reports,
our study showed that GPR87, a member of the GPCRs,
could activate NF-κB signaling pathway in pancreatic
cancer cells and that GPR87 levels were significantly
associated with NF-κB activity in clinical pancreatic
cancer tissues. However, the mechanism by which
GPR87 activates NF-κB signaling pathway has yet to beelucidated and is the subject of current investigations
by our group.
The mechanisms involved in GPR87 upregulation
also remain to be characterized. According to TCGA
[34], we found amplification of GPR87 in 25 of 184
cases, suggesting that amplification might account for
GPR87 overexpression in 13.59% of pancreatic cancer
patients. Interestingly, according to ChIP sequencing
tracks in the University of California Santa Cruz
(UCSC) genome browser (http://genome.ucsc.edu/cgi-
bin/hgGateway) [35], the promoter region of GPR87
showed STAT3 binding elements, suggesting that tumor
inflammatory microenvironment-mediated hyperactiva-
tion of JAK2/STAT3 signaling might contribute to GPR87
upregulation in pancreatic cancer. Thus, it would be of
great interest to further investigate whether upregulation
of GPR87 in pancreatic cancer is attributed to STAT3-
mediated transcriptional upregulation. Apart from overex-
pression of GPR87, ligands, such as lysophosphatidic acid
(LPA), in the tumor microenvironment may stimulate
GPR87 and subsequently lead to constitutive activation of
cancer-promoting signaling [36]. LPA is one of the most
potent mitogens secreted in the tumor-associated environ-
ment including the ascites fluid produced by ovarian can-
cer cells, stimulating the LPA-sensitive GPCRs that are
frequently overexpressed by these tumor cells and thus
contributing growth, survival and resistance to chemo-
therapy [37]. Meanwhile, a recent study also showed
that Gαi and Gαq contribute to GPR87-mediated NF-
κB activation in the 293 T cells, which is ligand-
independent [38], further support the notion that func-
tional NF-κB activation is critical for GPR87-mediated
cancer progression.
Conclusion
In summary, we reported that GPR87 expression was
significantly upregulated in pancreatic cancer, and higher
GPR87 correlated with shorter overall survival of pa-
tients with pancreatic cancer. Overexpression of GPR87
promotes proliferation, metastasis, angiogenesis and
resistance to apoptosis induced by a chemotherapeutic
agent in pancreatic cancer. Our findings suggest that
GPR87 plays a vital oncogenic role in pancreatic cancer
progression and highlight its potential as a target for
pancreatic cancer therapy.
Methods
Cell lines and cell culture
Human pancreatic cancer cell lines, including AsPC-1,
Capan-1, BxPC-3, Capan-2, PANC-1 and MIA PaCa-2
were grown in the DMEM medium (Invitrogen) supple-
mented with 10% fetal bovine serum (HyClone). Primary
cultures of normal human pancreatic ductal epithelial
cells (HPDECs) were maintained in keratinocyte serum-
Wang et al. Molecular Cancer  (2017) 16:61 Page 11 of 14free medium (KSFM; Invitrogen) with EGF (5 ng/ml)
and BPE (50 μg/ml). All cells were incubated at 37 °C in
a humidified atmosphere with 5% CO2.
Patient information and tissue specimens
A total of 96 paraffin-embedded and archived pancreatic
cancer samples, which were histopathologically and
clinically diagnosed at the Union Hospital, Huazhong
University of Science and Technology, from 2001.12 to
2009.01, were examined in this study. All the cases
were recruited only based on positive diagnosis of pan-
creatic cancer without other additional criteria, and all
the recruited cases were under standard treatment with
chemotherapeutic agent gemcitabine. Survival time
months correspond to time after diagnosis. Ten pairs of
matched pancreatic cancer/adjacent noncancerous tissues
and other 10 pancreatic cancer tissues were frozen and
stored in liquid nitrogen until further use. Clinical infor-
mation on the samples is summarized in Additional file 2:
Table S1. The use of human tissue was approved by the
local ethics committee (Tongji Medical College, China)
and written informed consent was obtained from patients
prior to surgery.
Vectors, retroviral infection and transfection
The human GPR87 gene was PCR-amplified from cDNA
and cloned into a pMSCV-puro retroviral vector and
GPR87-targeting short hairpin RNA (shRNA) oligonu-
cleotides sequences were cloned into pSuper-retro-puro
to generate pSuper-retro-GPR87-RNAi(s). pNF-κB-luc
and control plasmids (Clontech) were used to examine
NF-κB activity. pBabe-puro-IκBα-mut (plasmid#15291)
expressing IκBα dominant-negative mutant (IκBα-mut)
was purchased from Addgene (Cambridge, MA). Trans-
fection of siRNA or plasmids was performed using the
Lipofectamine 3000 reagent (Invitrogen) according to
the manufacturer’s instruction. Stable cell lines expressing
GPR87 or GPR87 RNAi were selected for 10 days with
0.5ug/ml puromycin 48 h after infection.
Western blotting analysis
Western blot was performed using anti-GPR87 (Abcam),
anti-p-IκBα, IκBα and anti-p-IKKβ, IKKβ, anti-p65,
anti-p84 antibodies (Cell Signaling Technology). The
membranes were stripped and re-probed with an anti-
α-tubulin antibody (Sigma) as a loading control.
Immunohistochemistry (IHC)
IHC analysis was performed to study altered protein
expression in 96 paraffin-embedded and archived pancre-
atic cancer with GPR87 antibody (Abcam, 1:500). The
degree of immunostaining of formalin-fixed, paraffin-
embedded sections were reviewed and scored separately
by two independent pathologists uninformed of thehistopathological features and patient data of the samples.
The scores were determined by combining the pro-
portion of positively-stained tumor cells and the
intensity of staining. The scores given by the two
independent pathologists were combined into a mean
score for further comparative evaluation. Tumor cell
proportions were scored as follows: 0, no positive
tumor cells; 1, <10% positive tumor cells; 2, 10%–35%
positive tumor cells; 3, 35–75% positive tumor cells;
4, >75% positive tumor cells. Staining intensity was
graded according to the following standard: 1, no
staining; 2, weak staining (light yellow); 3, moderate
staining (yellow brown); 4, strong staining (brown).
The staining index (SI) was calculated as the product
of the staining intensity score and the proportion of
positive tumor cells. Using this method of assessment,
we evaluated protein expression in malignant lesions
by determining the SI, with possible scores of 0, 2, 3,
4, 6, 8, 9, 12, and 16. Then the median value, SI = 8,
was chosen as the cut off value, which samples with
a SI ≥ 8 were determined as high expression and samples
with a SI < 8 were determined as low expression.Invasion assay
Transwell inserts for 24-well plates (Corning Costar
Corp., Cambridge, MA) were coated with prediluted
Matrigel (BD Biosciences, Bedford, MA) and allowed to
gel at 37 °C for 30 min. Cells were seeded at a density of
3 × 105 per insert and the lower chamber of the Trans-
well was filled with 500 μL DMEM supplemented with
10% FBS. After 24 h of incubation, cells remaining on
the upper surface of the Transwell membrane were
removed by a cotton swab. Cells that had invaded
through the Matrigel to the bottom of the insert were
fixed, stained, photographed and quantified by counting
them in 6 random high-powered fields.Chicken chorioallantoic membrane (CAM) assay
CAM assay was performed at day 6 of fertilized chicken
eggs using a method previously described [39]. A 1.0-cm
diameter window was opened on the egg shell (Huahao
Breeding Co. Ltd, Hubei, China). The surface of the der-
mic sheet on the floor of the air sac was removed to
expose the CAM. A 0.5-cm diameter filter paper was
first placed on top of the CAM, and 100 μl conditioned
medium was added onto the center of the paper. After
the window was closed with sterile adhesive tape, the
eggs were incubated at 37 °C under 80–90% relative
humidity for 4 days. Following fixation with stationary
solution (methanol: acetone = 1:1) for 15 min, the CAMs
were cut and harvested, and gross photos of each CAM
were taken with a digital camera (Panasonic, Osaka,
Japan). The effect of conditioned media harvested from
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second- and third-order vessels.
HUVEC tube formation assay
Briefly, 200 μl of precooled Matrigel (Collaborative
Biomedical Products) was transferred into each well of a
24-well plate and polymerized for 30 min at 37 °C.
HUVECs (2 × 104) in 200 μl of conditioned medium
were added to each well and incubated at 37 °C, 5% CO2
for 20 h. The capillary tube structure was photographed
under a 100 × bright-field microscope, and quantified by
measuring the total length of the completed tubes. Each
condition was assessed in triplicate.
Animal studies, IHC, and H&E staining
BALB/c-nu mice (4–5 weeks of age, 18-20 g) were pur-
chased from Vitalriver (Beijing, China). All experimental
procedures were approved by the Ethics Committee of
Tongji Medical College, Huazhong University of Science
and Technology. The BALB/c nude mice were randomly
divided into two groups (n = 6/group). One group of
mice was inoculated subcutaneously with PANC-1/Vector
cells (2 × 106) in the left dorsal flank and with PANC-1/
GPR87 cells (2 × 106) in the right dorsal flank per mouse.
Another group was inoculated subcutaneously with
PANC-1/RNAi-vector cells (2 × 106) in the left dorsal
flank and with PANC-1/GPR87-RNAi cells (2 × 106) in
the right dorsal flank. Tumors were examined twice
weekly; length and width measurements were obtained
with calipers and tumor volumes were calculated using
the equation (L ×W2)/2. On day 36, tumors were detected
by an IVIS imaging system, and animals were euthanized,
tumors were excised, weighed and paraffin-embedded.
Serial 6.0 μm sections were cut and subjected to IHC ana-
lyzed using an anti-Ki67 and anti-CD31 antibodies (Dako).
Proliferation index was quantized by counting proportion
of Ki67-positive cells. Apoptotic index was measured by
percentage of TUNEL-positive cells.
Microarray data process and analysis
The publicly-available gene expression dataset GSE16515
was assessed through the Gene Expression Omnibus
(GEO) Datasets website http://www.ebi.ac.uk/arrayex-
press/experiments/E-GEOD-16515/?query=gse16515.
This array consists of 36 tumor samples and 16 normal
samples; a total of 52 samples. 16 samples consist of both
tumor and normal expression data, whereas 20 samples
consist of only tumor data. This microarrays was used to
identify the expression differences of genes between the
pancreatic tumor and normal samples.
Statistical analysis
Statistical tests for data analysis included Fisher’s exact
test, log-rank test, Chi-square test, and Student’s 2-tailedt test. Statistical analyses were performed using the SPSS
11.0 statistical software package. Data represent mean ±
SD. p < 0.05 was considered statistically significant.Additional files
Additional file 1: Figure S1. mRNA expression analysis shows that
GPR87 was up-regulated in pancreatic cancer tissues and cell lines. A.
Real-time PCR analysis of GPR87 expression in two human pancreatic
ductal epithelial cells (HPDECs) and in pancreatic cancer cell lines
(AsPC-1, Capan-1, BxPC-3, Capan-2, PANC-1 and MIA PaCa-2). B. Real-time
PCR analysis of GPR87 expression in pancreatic cancer tissues (T) with
matched adjacent non-tumor tissues (N) from 8 patients. Transcript levels
were normalized to GAPDH expression. Each bar represents the mean ±
SD of three independent experiments. * p < 0.05. (TIF 110 kb)
Additional file 2: Table S1. Clinicopathological characteristics of studied
patients and expression of GPR87 in pancreatic cancer. (DOC 41 kb)
Additional file 3: Table S2. Correlation between the clinicopathological
features and expression of GPR87. (DOC 41 kb)
Additional file 4: Figure S2. Annexin V-FITC and PI staining of indicated
cells with or without Fluorouracil treatment. A. Representative images
(left panel) and quantification (right panel) of Annexin V-FITC and PI staining
of indicated cells with no treatment for 24 h. B. Representative images (left
panel) and quantification (right panel) of Annexin V-FITC and PI staining of
indicated cells treated with Fluorouracil for 24 h. Each bar represents the
mean ± SD of three independent experiments. * p < 0.05. (TIF 508 kb)
Additional file 5: Figure S3. Western blot analysis of GPR87 expression
in the indicated xenografts tumors. (TIF 166 kb)
Additional file 6: Figure S4. GPR87 up-regulation activates the NF-κB
signaling pathway in pancreatic cancer. GSEA plot, indicating a significant
correlation between the mRNA levels of GPR87 expression in pancreatic
cancer and the NF-κB-activated gene signatures in multiple published
datasets. (TIF 316 kb)
Additional file 7: Figure S5. Effects of Inhibiting NF-κB signaling in the
indicated cells. A. Quantification of colony numbers as determined by
anchorage-independent growth assay. Colonies larger than 0.1 mm in
diameter were scored. B. Quantification of tubule formation by HUVECs
cultured in matrigel-coated plates with conditioned media from pancreatic
cancer cells transfected with the vector, IκBα-mut or treated with the NF-κB
inhibitor (JSH-23). C. Quantification of gemcitabine-induced (1 μM) TUNEL-
positive cells in pancreatic cells transfected with vector, IκBα-mut or treated
with the NF-κB inhibitor. Each bar represents the mean ± SD of three
independent experiments. * p < 0.05. (TIF 288 kb)
Additional file 8: Figure S6. Overexpressing GPR87 promotes
proliferation and induces HUVEC tube formation in HPDEC cells and
Eca109. A. Western blot of GPR87 expression in HPDEC-1 cells transfected
with GPR87 or a vector control. α-tubulin was used as a loading control. B.
Quantification of BrdU labeling in HPDEC-1 cells transfected with GPR87 or
a vector control. C. Quantification of HUVECs cultured on matrigel-coated
plates with conditioned medium from vector control or GPR87 transfected
HPDEC-1 cells. D. Western blot of GPR87 expression in Eca109 cells
transfected with GPR87, GPR87-RNAi or their corresponding controls.
α-tubulin was used as a loading control. E. Quantification of BrdU labeling
in indicated cells. F. Quantification of HUVECs cultured on matrigel-coated
plates with conditioned medium from indicated cells. (TIF 396 kb)Abbreviations
CAM: Chicken chorioallantoic membrane; ESCC: Esophageal squamous cell
carcinoma; GEO: Gene expression Omnibus; GPCR: G protein-coupled
receptor; HPDECs: Human pancreatic ductal epithelial cells; HUVEC: Human
umbilical vein endothelial cell; IHC: Immunohistochemistry; LPA: Lysophosphatidic
acid; MVD: Microvascular density; NSCLC: Non-small cell lung carcinoma;
TCGA: The cancer genome Atlas; UCSC: the University of California Santa
Cruz (UCSC)
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